ERBB2 and neoplasm: Although MLN4924 has been reported to be an activator of the oncogenic AKT pathway, which is responsible for tumour progression and drug resistance, in HER2-positive and triple-negative breast cancer cell lines38, our data showed that the NEDDylation inhibitor can effectively repress ER-positive and triple-negative breast cancer cell proliferation, clonogenicity and cell migration.